The impetus to develop useful models of human disease and toxicity has resulted in a number of large-scale mouse mutagenesis programmes. This, in turn, has stimulated considerable concern regarding the scientific validity and welfare of genetically altered mice, and the large numbers of mice that are required by such programmes. In this paper, the scientific advantages and limitations of genetically altered mice as models of several human diseases are discussed. We conclude that, while the use of some such mouse models has contributed considerably to an understanding of human disease and toxicity, other genetically altered mouse models have limited scientific relevance, and fewer have positively contributed to the development of novel human medicines. Suggestions for improving this unsatisfactory situation are made.
The Baylor College of Medicine (2006). The Baylor College of Medicine Mouse Mutagenesis Project. Website http://www.mouse-genome.bcm.tmc.edu/ (Accessed 3.05.06).
6.
Jackson Laboratory (2006). The Mouse Heart, Lung, Blood and Sleep Disorders Center. Website http://pga.jax.org/ (Accessed 3.05.06).
MephamT.B., CombesR.D., BallsM., BarbieriO., BlokhuisH.J., CostaP., CrillyR.E., de Cock BuningT., DelphireC., O'HareM.J., HoudebineL-M., van KreijlC.F., van der MeerM., ReinhardtC.A., WolfE., & van ZellerA-M. (1998). The use of transgenic animals in the European Union. The Report and Recommendations of ECVAM Workshop 28. ATLA26, 21–43.
15.
DragunskyE., NomuraT., KarpinskiK., FureszJ., WoodD.J., PerivikovY., AbeS., KurataT., VanloockeO., KarganovaG., TaffsR., HeathA., IvshinaA., & LevenbookI. (2003). Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: Validation by a WHO collaborative study. Bulletin of the World Health Organisation81, 251–262.
16.
GreavesD.R., FraserP., VidalM.A., HedgesM., RopersD., LuzzattoL., & GrosveldF. (1990). A transgenic mouse model of sickle cell disorder. Nature, London11, 183–185.
17.
TrudelM., SaadaneN., GarelM.C., Bardakdjian-MichauJ., BlouquitY., Guerquin-KernJ.L., Rouyer-FessardP., VidaudD., PachnisA., RomeoP.H., BeuzardY., & CostantiniF. (1999). Towards a transgenic mouse model of sickle cell disease: Hemoglobin SAD. EMBO Journal10, 3157–3165.
18.
PasztyC., BrionC.M., ManciE., WitowskaH.E., StevensM.E., MohandasN., & RubinE.M. (1997). Transgenic knockout mice with exclusively human sickle haemoglobin and sickle cell disease. Science, New York278, 876–878.
19.
ManciE.A., HillieryC.A., BodianC.A., ZhangZ.G., LuttyG.A., & CollerB.S. (2006). Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood107, 1651–1658.
20.
MelanitouE. (2005). The autoimmune contrivance: Genetics in the mouse model. Clinical Immunology117, 195–206.
21.
WhitacreC.C. (2001). Sex differences in autoimmune disease. Nature Immunology2, 777–780.
22.
WickerL.S., ClarkJ., FraserH.I., GarnerV.E.S., Gonzalez-MunozA., HealyB., HowlettS., HunterK., RainbowD., RosaR.L., SminkL.J., ToddJ.A., & PetersonL.B. (2005). Type 1 diabetes genes and pathways shared by humans and NOD mice. Journal of Autoimmunity25, 29–33.
23.
KanezakiY., ObataT., MatsushimaR., MinamiA., YuasaT., KishiK., BandoY., UeharaH., IzumiK., MitaniT., MatsumotoM., TakeshitaY., NakayaY., MatsumotoT., & EbinaY. (2004). KATP channel knockout mice crossbred with transgenic mice expressing a dominant negative form of human insulin receptor have glucose intolerance but not diabetes. Endocrine Journal51, 133–144.
24.
HiotaC., LarssonO., SheltonK.D., ShiotaM., EfanovA.M., HoyM., LindnerJ., KooptiwutS., Juntti-BerggrenL., GromadaJ., BerggrenP-O., & MagnusonM.A. (2002). Sulfonylurea Receptor Type 1 Knock-out Mice Have Intact Feeding-stimulated Insulin Secretion despite Marked Impairment in Their Response to Glucose. Journal of Biological Chemistry277, 37176–37183.
25.
KelbigM.l., WilkinsonJ.E., GeislerJ.G., & WoychikR.P. (1995). Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proceedings of the National Academy of Sciences of the USA92, 4728–4732.
26.
KeremB., RommensJ.M., BuchananJ.A., MarkiewiczD., CoxT.K., ChakravartiA., BuchwaldM., & TsuiL.C. (1989). Identification of the cystic fibrosis gene: genetic analysis. Science, New York245, 1073–1080.
SnouwaertJ.N., BrigmanK.K., LatourA.M., MaloufN.N., BoucherR.C., SmithiesO., & KollerB.H. (1992). An animal model for cystic fibrosis made by gene targeting. Science, New York257, 1083–1088.
29.
RozmahelE., GyomoreyK., PlyteS., NguyenV., WilschanskiM., DurieP., BearC.E., & TsuiL.C. (1997). Incomplete rescue of cystic fibrosis transmembrane conductance regulator deficient mice by the human CFTR cDNA. Human Molecular Genetics6, 1153–1162.
30.
AmeenN., AlexisJ., & SalasP. (2000). Cellular localisation of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. Histochemistry & Cell Biology114, 69–75.
KunzelmannK., SchreiberR., KönigJ., & MallM. (2002). Ion Transport Induced by Proteinase-Activated Receptors (PAR2) in Colon and Airways. Cell Biochemistry and Biophysics36, 209–214.
33.
BootH.J., KasteelD.T.J., BuismanA-M., & KimmanT.G. (2003). Excretion of wild-type and vaccine-derived poliovirus in the faeces of poliovirus receptor-transgenic mice. Journal of Virology77, 6541–6545.
34.
JenkinsE.S., & CombesR.D. (1999). The welfare problems associated with using transgenic mice to bioassay for bovine spongiform encephalopathy. Animal Welfare8, 421–431.
35.
MestasJ., & HughesC.C.W. (2004). Of mice and not men: Differences between mouse and human immunology. Journal of immunology172, 2731–2738.
36.
PerkinsJ.D. (2006). Infection by proxy: The role of chimeric mice in HBV and HCV research. Liver Transplantation12, 323.
37.
ChangL.J., & ZhangC. (1995). Infection and replication of tat-minus human immunodeficiency viruses: genetic analyses of LTR and tat GAs in primary and long-term human lymphoid cells. Virology211, 157–169.
38.
MeulemanP., LibbrechtL., De VosR., de HemptinneB., GevaertK., VandekerckhoveJ., RoskamsT., & Leroux-RoelsG. (2005). Infection by Proxy: The Role of Chimeric Mice in HBV and HCV Research. Morphological and biochemical characterization of a human liver in a uPASCID mouse chimera. Hepatology41, 847–856.
39.
Ayash-RashkovskyM., BentwichZ., ArdittiF., FriedmanS., ReisnerY., & BorkowG. (2005). A novel small animal model for HIV-1 infectionFASEB Journal express article 10.1096/fj.04-3184fje.
40.
KlotmanP.E., & NotkinsA.L. (1996). Transgenic models of human immunodeficiency. Current Topics in Microbiology & Immunology206, 197–222.
41.
PotashM.J., ChaoW., BentsmanG., ParisN., SainiM., NitkiewiczJ., BelemP., SharerL., BrooksA.I., & VolskyD.J. (2005). A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proceedings of the National Academy of Sciences of the USA102, 3760–3765.
42.
RouquierS., BlancherA., & GiorgiD. (2000). The olfactory receptor gene repertoire in primates and mouse: Evidence for reduction of the functional fraction in primates. Proceedings of the National Academy of Sciences of the USA97, 2870–2874.
43.
GiladY., WiebelV., PrzeworskiM., LancetD., & PaaboS. (2004). Loss of olfactory receptor genes coincides with the acquisition of full trichromatic vision in primates. PloS Biology2, 120–125.
44.
FinbergK.E., WagnerC.A., BaileyM.A., PaunescuT.G., BretonS., BrownD., GiebischG., GeibelJ.P., & LiftonR.P. (2005). The B1-subunit of the H+ ATPase is required for maximal urinary acidification. Proceedings of the National Academy of Sciences of the USA102, 13616–13621.
45.
DouH., FinbergK., CardellE.L., LiftonR., & ChooD. (2003). Mice lacking the B1 subunit of H+-ATPase have normal hearing. Hearing Research180, 76–84.
46.
RufR., RensingC., TopalogluR., Guay-WoodfordL., KleinC., VollmerM., OttoE., BeekmannF., HallerM., WiedensohlerA., LeumannE., AntignacC., RizzoniG., FillerG., BrandisM., WeberJ.L., & HildebrandtF. (2003). Confirmation of the ATP6B1 gene as responsible for distal renal tubular acidosis. Pediatric Nephrology18, 105–109.
47.
GibsonF., WalshJ., MburuP., VarelaA., BrownK.A., AntonioM., BeiselK.W., SteelK.P., & BrownS.D. (1995). A type VII myosin encoded by the mouse deafness gene shaker-1. Nature, London374, 62–64.
48.
ElAmraouiA., SahlyI., PicaudS., SahelJ., AbitbolM., & PetitC. (1996). Human Usher 1B mouse shaker-1: The retinal phenotype discrepancy explained by the presence/absence of myosin VIIA in the photoreceptor cells. Human Molecular Genetics5, 1171–1178.
49.
LibbyR.T., & SteelK.P. (2001). Electroretinographic anomalies in mice with mutations in myo7a, the gene involved in human Usher syndrome type 1B. Investigative Ophthalmology & Visual Science42, 770–778.
50.
SungC-H., MakinoC., BaylorD., & NathansJ. (1994). A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. Journal of Neuroscience14, 5818–5833.
51.
DalkeC., & GrawJ. (2005). Mouse mutants as models for congenital retinal disorders. Experimental Eye Research81, 503–512.
52.
JacobsG.H., NeitzJ., & DeeganJ.F. (1991). Retinal receptors in rodents maximally sensitive to ultraviolet light. Nature, London353, 655–656.
53.
CooperB.J. (1989). Animal models of Duchenne and Becker muscular dystrophy. British Medical Bulletin45, 703–718.
54.
DaingainJ., & VrbovaG. (1984). Muscle development in mdx GA mice. Muscle & Nerve7, 700–704.
55.
ElbrinkJ., MalhotraS.K., & HunterE.G. (1987). Duchenne muscular dystrophy: Assessment of experimental data from animals in relation to the human disease. Medical Hypotheses23, 131–136.
56.
GardnerK.L., KearneyJ.A., EdwardsJ.D., & Rafael-FortneyJ.A. (2006). Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy. Gene Therapy13, 744–751.
57.
RichardsonJ.A., & BurnsD.K. (2002). Mouse Models of Alzheimer's Disease: A Quest for Plaques and Tangles. ILAR Journal43, 89–99.
58.
HolcombL., GordonM.N., McGowanE., YuX., BenkovicS., JantzenP., WrightK., SaadI., MuellerR., MorganD., SandersS., ZehrC., O’ CampoK., HardyJ., PradaC-M., EckmanC., YounkinS., HsiaoK., & DuffK. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both GA amyloid precursor protein and presenelin 1 transgenes. Nature Medicine4, 97–100.
59.
GotzJ., ChenF., van-DorpeJ., & NitschR.M. (2001). Tau filament formation in transgenic mice expressing P301L tau. Journal of Biological Chemistry276, 529–534.
60.
ItzhakiR.F., WozniakM.A., AppeltD.M., & BalinB.J. (2004). Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiology of Aging25, 619–627.
61.
ThyagarajanT., ToteyS., DantonM.J.S., & KulkarniA.B. (2003). Genetically altered mouse models: The good, the bad and the ugly. Critical Reviews in Oral Biology & Medicine14, 154–174.
62.
SatokataI., & MaasR. (1994). Msx-1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nature Genetics6, 348–356.
63.
AngY., XiaoR., YangF., KarimB.O., IacovelliA.J., CaiJ., LernerC.P., RichtsmeierJ.T., LesziJ.M., HillC.A., YuK., OrnitzD.M., lisseeffJ., HusoD.L., & JabsE.W. (2005). Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse. Development132, 3537–3548.
64.
EpsteinC.J., CoxD.R., & EpsteinL.B. (1985). Mouse trisomy 16: An animal model of human trisomy 21 (Down syndrome). Annals of the New York Academy of Sciences450, 157–168.
65.
BacchusC., SterzH., BuselmaierW., SahaiS., & WinkingH. (1987). Genesis and systematization of cardiovascular anomalies and analysis of skeletal malformations in murine trisomy 16 and 19: Two animal models for human trisomies. Human Genetics77, 12–22.
66.
WallerB.R.III, McQuinnT., PhelpsA.L., MarkwaldR.R., LoC.W., ThompsonR.P., & WesselsA. (2000). Conotruncal Anomalies in the Trisomy 16 Mouse: An Immunohistochemical Analysis with Emphasis on the Involvement of the Neural Crest. The Anatomical Record260, 279–293.
67.
AkesonE.C., LambertJ.P., NarayanswamiS., GardinerK., BechtelL.J., & DavissonM.T. (2001). Ts65Dn — localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenetics & Cell Genetics93, 270–276.
68.
HoltzmanD.M., SantucciD., KilbridgeJ., Chua-CouzensJ., FontanaD.J., DanielsS.E., JohnsonR.M., ChenK., SunY., CarlsonE., AllevaE., EpsteinC.J., & MobleyW.C. (1996). Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proceedings of the National Academy of Sciences of the USA93, 13333–13338.
69.
HunterC.L., Bimonte-NelsonH.A., NelsonM., EckmanC.B., & GranholmA-C. (2004). Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiology of Aging25, 873–884.
70.
O'DohertyA., RufS., MulliganC., HildrethV., ErringtonM.L., CookeS., SesayA., ModinoS., VanesL., HernandezD., LinehanJ.M., SharpeP.T., BrandnerS., BlissT.V.P., HendersonD.J., NizeticD., TybulewiczV.L.J., & FisherE.M.C. (2005). An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science, New York309, 2033–2037.
71.
MarinoB. (1993). Congenital heart disease in patients with Down's Syndrome: anatomic and genetic aspects. Biomedicine and Pharmacotherapy47, 197–200.
72.
OlsonL.E., RichtsmeierT., LeszlJ., & ReevesR.H. (2004). A chromosome 21 critical region does not cause specific down syndrome phenotypes. Science, New York306, 687–690.
73.
LundkvistJ., ZhuS., HanssonE.M., SchweinhardtP., QingM., BeatusP., DannaeusK., KarlstromH., JohanssonC.B., ViitanenM., RozellB., SpengerC., MohammedA., KalimoH., & LendahlU. (2004). Mice carrying a R142C Notch 3 knock-in mutation do not develop a CADASIL-like phenotype. Genesis41, 13–22.
74.
LiY., ErzurumiR.S., ChenC., JhaveriS., & TonegawaS. (1994). Whisker-related neuronal patterns fail to develop in the trigeminal brainstem of NMDAR1 knockout mice. Cell76, 427–437.
75.
TsienJ.Z., HuertaP.T., & TonegawaS. (1996). The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell87, 1327–1338.
76.
KroeseE.D., van SteegH., van OostromC.T., DortantP.M., WesterP., van KranenH.J., de AriesA., & van KreijlC.F. (1997). Use of E-pim transgenic mice for short-term in vivo carcinogenicity testing: Iymphoma induction by benzo[a]pyrene but not TPA. Carcinogenesis19, 975–908.
77.
MacDonaldJ.S. (2004). Human Carcinogenic Risk Evaluation, Part IV: Assessment of Human Risk of Cancer from Chemical Exposure Using a Global Weight-of-Evidence Approach. Toxicological Sciences82, 3–8.
78.
YamamotoS., MitsumoriK., KodamaY., MatsunumaN., ManabeS., OkamiyaH., SuzukiH., FukudaT., SakamakiY., SunagaM., NomuraG., HiokiK., WakanaS., NomuraT., & HayashiY. (1996). Rapid Induction of More Malignant Tumors by Various Genotoxic Carcinogens in Transgenic Mice Harboring a Human Prototype c-Ha-ras Gene Than in Control Non-Transgenic Mice. Carcinogenesis17, 2455–2461.
79.
Jacobson-KramD., SistareF.D., & JacobsA.C. (2004). Use of transgenic mice in carcinogenicity hazard assessment. Toxiological Pathology32, Suppl. 1, 49–52.
80.
ICH (1997). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Guideline S1BTesting for Carcinogenicity in Pharmaceuticals.11 pp. Website http://www.ich.org (Accessed 2.06.05).
81.
WahnschaffeU., BitschA., KielhornJ., & MangelsdorfI. (2005). Mutagenicity testing with transgenic mice. Part I: Comparison with the mouse bone marrow micronucleus test. Journal of Carcinogenesis4, doi:10.1186/1477-3163-4-3. Website http://www.carcinogenesis.com/content/4/1/3 (Accessed 25.05.06).
82.
WahnschaffeU., BitschA., KielhornJ., & MangelsdorfI. (2005). Mutagenicity testing with transgenic mice. Part II: Comparison with the mouse spot test. Journal of Carcinogenesis4, doi:10.1186/1477-3163-4-4. Website http://www.carcinogenesis.com/content/4/1/4 (Accessed 25.05.06).
AttardiL.D., & JacksT. (1999). The role of p53 in tumour suppression: lessons from mouse models. Cellular and Molecular Life Sciences55, 48–63.
85.
Van DykesJ., & JacksJ. (2002). Cancer Modelling in the Modern Era: Progress and Challenges. Cell108, 135–144.
86.
FlanaganS.P. (1966). ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genetic Research8, 295–309.
87.
HudsonM. (2005). The welfare and scientific advantages of non-invasive imaging of animals used in biomedical research. Animal Welfare14, 303–317.
88.
LehmannA.R. (2003). DNA repair-deficient disease, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie85, 1101–1111.
89.
Van KreijlC.F., McAnultyP.A., BeemsR.B., VynckierA., van SteegH., Fransson-SteenR., AldenC.L., ForsterR., van der LaanJ-W., & VandenbergheJ. (2001). Xpa and Xpa/p53+/- Knockout mice: overview of available data. Toxicological Pathology29, 117–127.
90.
Van der HorstG.T.J., van SteegH., BergR.J.W., van GoolA.J., de WitJ., WeedaG., MorreauH., BeemsR.B., van KreijlC.F., de GruijlF.R., OotsmaD., & HoeijmakersJ.H.J. (1997). Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell89, 425–435.
91.
MansourS.L., ThomasK.R., & CapecchiM.R. (1988). Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature, London336, 348–352.
92.
CoxD.R., & PalmiterR.D. (1982). Assignment of the mouse metallothionein-1 gene to chromosome-8 é Implications for human Menkes disease. Clinical Research30, A117–A117.
93.
EpsteinC.J., CoxD.R., & EpsteinL.B. (1985). Mouse trisomy 16: An animal model of human trisomy 21 (Down syndrome). Annals of the New York Academy of Sciences450, 157–168.
